Use of individual components and advances in topical formulation technology: Focus on corticosteroids

Cosmetic Dermatology

Volumn 19, Issue 11, 2006, Pages 677-680

  Del Rosso, James Q ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF NEVADA   (United States)

^b Coria Laboratories Ltd ^*  (Spain)

^c Galderma Laboratories   (United States)

^d Intendis GmbH   (Germany)

^e Medicis Pharmaceutical Corporation   (United States)

^f Stiefel Laboratories Inc   (United States)

^g Warner Chilcott Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AZELAIC ACID; BETA CYCLODEXTRIN; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CLINDAMYCIN; CLOBETASOL PROPIONATE; COCAMIDOPROPYL BETAINE; CORTICOSTEROID; FLUOCINONIDE; METRONIDAZOLE; MYRISTIC ACID ISOPROPYL ESTER; NICOTINAMIDE; PROPYLENE GLYCOL; RETINOIC ACID; SALICYLIC ACID; SHAMPOO;

AEROSOL; CREAM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; EMULSION; FOAM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROGEL; LOTION; OINTMENT; PHARMACEUTICAL ENGINEERING; PSORIASIS; REVIEW; SKIN DISEASE; SKIN PENETRATION; TECHNOLOGY; VASOCONSTRICTION;

EID: 33846945783     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006;5:527-532.
2. Franz TJ, Parsell DA, Myers JA, et al. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol. 2000;39:535-538.
3. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628-632.
4. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-583.
5. Nyirady J, Lucas C, Yusuf M, et al. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis. 2002;70:295-298.
6. Shalita AR, Myers JA, Krochmal L, et al. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol. 2005;4:48-56.
7. Del Rosso JQ. Management of truncal acne vulgaris: current perspectives on treatment. Cutis. 2006;77:285-289.
8. Del Rosso JQ. Current therapies and research for common dermatologic conditions: the many roles of topical salicylic acid. Skin Aging. 2005;13:38-42.
9. Dow G, Basu S. A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3). Cutis. 2006;77:18-26.
10. Draelos ZD, Graupe K. A new topical formulation for the treatment of mild to moderate papulopustular rosacea: azelaic acid 15% gel. Poster presented at: American Academy of Dermatology 61st Annual Meeting; March 21-26, 2003; San Francisco, Calif.
11. Vanos (fluocinonide) Cream 0.1% [package insert]. Scottsdale, Ariz: Medicis Pharmaceutical Corp; 2005.
12. Del Rosso JQ, Bikowski J. A thorough analysis of individual components used in vehicle formulations: why they are there and what they do. Poster presented at: American Academy of Dermatology Summer Meeting; July 27-30, 2006; San Diego, Calif.
13. Clobex (clobetasol propionate) Lotion 0.05% [package insert]. Fort Worth, Tex; Galderma Laboratories LP; 2004.
14. Clobex (clobetasol propionate) Spray 0.05% [package insert]. Fort Worth, Tex: Galderma Laboratories LP; 2006.
15. Clobex (clobetasol propionate) Shampoo 0.05% [package insert]. Fort Worth, Tex: Galderma Laboratories LP; 2004.
16. Taclonex (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment. Rockaway, NJ: Warner Chilcott; 2006.
17. Patel B, Siskin S, Krazmien R, et al. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol. 1998;38:1010-1011.
18. Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol. 2004;43:611-617.
19. Huang X, Tanojo H, Lenn J, et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol. 2005;53(suppl): S26-S38.
20. Marks JG, DeLeo VA. Contact and Occupational Dermatology. St Louis, Mo: Mosby-Year Book; 1992.
21. Rietschel RL, Fowler JF, Fisher AA. Fisher's Contact Dermatitis. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001.